Track: Life Sciences
Life Science Panel: Future of Artificial Intelligence in the Life Science Industry
Wednesday, April 14, 2-2:40pm EDT
In this panel, we will discuss the impact Artificial Intelligence is making on the Life Science industry, from drug discovery to commercial operations. We will explore how pharmaceutical companies plan to leverage AI to power their business in the future. Panel will be comprised of senior leaders from the pharmaceutical industry who have responsibility to shape AI for their organizations and the industry.
Tatiana Sorokina
Moderator: Tatiana Sorokina
Solutions Director, Data Science & Artificial Intelligence at Novartis
Tatiana is a Solutions Director for Data Science & AI at Novartis. She is a data science evangelist, a former entrepreneur and a digital transformation leader in healthcare. At Novartis, Tatiana has held various roles in data science, ranging from early drug discovery to commercial and marketing. Prior to Novartis, Tatiana founded Parceed, an AI assistant to medical students, and led data science at Prognos, the largest lab data aggregator in the United States.
Tatiana is a blogger, a public speaker on data & digital and an educator. She is an Adjunct Professor of AI in Marketing at Rutgers Business School and an Associate Instructor of Data Analytics at Brainstation. Tatiana also serves on the Board of Directors of Pharmaceutical Management Science Association (PMSA). She holds Master of Science degree from Columbia Business School and Bachelor of Science from Moscow State University.
Iya Khalil
Panelist: Iya Khalil
Global Head of the AI Innovation Center at Novartis
Dr. Iya Khalil is a technology entrepreneur and physicist with a vision of transforming medicine and healthcare into a discipline that is quantitative, predictive, and patient-centric via AI and big data. She co-founded two AI and machine learning companies, Gene Network Sciences Inc. and GNS Healthcare, and is the co-inventor of the proprietary AI and machine learning software platform that underpins both entities. Dr. Khalil’s machine learning and AI expertise spans 18 years with applications in drug discovery, drug development, clinical trial optimization, real world evidence and pharmaceutical commercial applications, and all the way to treatment algorithms that can be applied at the point of care. She was recognized by President Obama at a White House dinner as a leading entrepreneur in genomic medicine, named to Inc’s magazine list of top female founders of 2018 as well as more recently in the Forbes 2019 top women-led startups crushing tech.
Faisal Khan
Panelist: Faisal Khan
Executive Director, Advanced Analytics and AI at AstraZeneca
Faisal M. Khan, Ph.D. is the Executive Director of Advanced Analytics and Artificial Intelligence at Astrazeneca. His team focuses on the applications of AI and data science throughout the drug discovery lifecycle, from target identification through Phase 3 trials and beyond, including in Digital Health. His interests focus on the intersections of data science, biostatistics, bioimaging, personalized medicine, and healthcare delivery. His career has encompassed all aspects of healthcare and biomedical analytics, including diagnostics, devices, clinical trials/therapeutics, digital health and payers/insurance. Dr. Khan has worked or consulted across academia and industry with both startups and Fortune-50 companies. He has over 90 published papers, abstracts, and patents
Ranjit Kumble
Panelist: Ranjit Kumble
VP, Scientific/Clinical Analytics and Analytic Innovation at Pfizer
Ranjit Kumble is Vice President of Scientific/Clinical Analytics and Analytic Innovation at Pfizer. Ranjit’s career has focused on the advancement of global enterprise Data Science capabilities and his tenure at Pfizer has included leadership roles in strategic analytics and advanced analytics. In addition to his responsibilities at Pfizer, Ranjit is Adjunct Faculty with the Applied Analytics program at Columbia University’s School of Professional Studies. Prior to Pfizer, Ranjit worked as a management consultant at ZS Associates and was an NIH Research Fellow in Biophysics at the University of Pennsylvania. Ranjit holds a B.Sc. (Honors) degree in Chemistry from St. Stephen’s College, Delhi, India and a Ph.D. in Physical Chemistry from Princeton University.
Fernando Schwartz
Panelist: Fernando Schwartz
Global Head of Data Science at Merck
Fernando is the Global Head of Data Science for Human Health at Merck (AVP), where he leads the Innovation at Scale team within Commercial Data and Analytics. His team leverages innovative AI/ML technologies to address high impact/high value global challenges within the evolving healthcare ecosystem. Fernando has C-level experience building and overseeing data science teams in biopharma, healthcare technology, and online advertisement (adtech). Prior to working in industry, he held academic positions at Stanford University, Duke University, University of Warwick (UK), IMPA (Brazil), and the University of Tennessee, where he was a tenured professor of mathematics & data science. Fernando received his Ph.D. in mathematics from Cornell University, and M.S. and B.S. in engineering from the University of Chile.
Inder Singh
Panelist: Inder Singh
Global Oncology Vice President of Digital, Insights & Analytics at Takeda
Inder Singh is Vice President of Digital, Insights & Analytics at Takeda Global Oncology, a biopharma company focused on serving cancer patients. Inder has extensive strategy & analytics experience with a proven track record of building strong teams and improving the businesses on which he works. Inder previously worked at Novartis where he was the Head of Data Science and Forecasting COE. Inder has also worked at Accenture, ZS Associates and Bristol Myers Squibb. While at Accenture, Inder was awarded US patent for predictive analytics invention entitled “Intelligent Collections Model” using credit and tax data to predict tax defaulters who will pay during collections process. Inder earned a Master’s degree in Quantitative Economics from Emory University, Atlanta. Inder also received a Master’s degree in Management from Yale University specializing in quantitative marketing and strategy.
